EFFIMUNE has a total of 14 patent applications. Its first patent ever was published in 2010. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and United States. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are LIVZON MABPHARM INC, SHANGHAI INST OF IMMUNOLOGY and PFEIFER ANDREA.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 7 | |
#2 | WIPO (World Intellectual Property Organization) | 3 | |
#3 | United States | 2 | |
#4 | Canada | 1 | |
#5 | China | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Analysing materials | |
#5 | Climate change adaptation technologies |
# | Name | Total Patents |
---|---|---|
#1 | Vanhove Bernard | 14 |
#2 | Mary Caroline | 12 |
#3 | Poirier Nicolas | 12 |
#4 | Brouard Sophie | 4 |
#5 | Mai Le Hoa | 4 |
#6 | Soulillou Jean-Paul | 3 |
#7 | Froger Josy-Anne | 1 |
#8 | Gascan Hugues | 1 |
#9 | Danger Yannick | 1 |
#10 | Coulon Flora | 1 |
Publication | Filing date | Title |
---|---|---|
EP2955196A1 | Antibodies directed against CD127 | |
EP3012271A1 | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases | |
EP2583980A1 | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates | |
EP2583979A1 | Methods to prepare antibodies directed against p19 subunit of human IL-23 | |
EP2486059A1 | Monovalent ligands of the human cd28 receptor |